UBS Group’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-173,132
| Closed | -$225K | – | 10299 |
|
|
2025
Q2 | $225K | Sell |
173,132
-108,825
| -39% | -$131K | ﹤0.01% | 6645 |
|
|
2025
Q1 | $392K | Buy |
281,957
+196,788
| +231% | +$431K | ﹤0.01% | 6046 |
|
|
2024
Q4 | $195K | Buy |
85,169
+78,125
| +1,109% | +$207K | ﹤0.01% | 6464 |
|
|
2024
Q3 | $19.2K | Sell |
7,044
-1,118
| -14% | -$2.73K | ﹤0.01% | 7401 |
|
|
2024
Q2 | $19.1K | Sell |
8,162
-13,287
| -62% | -$42.4K | ﹤0.01% | 7332 |
|
|
2024
Q1 | $101K | Sell |
21,449
-3,948
| -16% | -$20.5K | ﹤0.01% | 6223 |
|
|
2023
Q4 | $124K | Buy |
25,397
+15,289
| +151% | +$63.5K | ﹤0.01% | 6056 |
|
|
2023
Q3 | $47K | Buy |
10,108
+664
| +7% | +$3.82K | ﹤0.01% | 6327 |
|
|
2023
Q2 | $69.8K | Buy |
9,444
+5,286
| +127% | +$35.3K | ﹤0.01% | 6273 |
|
|
2023
Q1 | $34K | Buy |
4,158
+2,527
| +155% | +$26.4K | ﹤0.01% | 6711 |
|
|
2022
Q4 | $15.6K | Buy |
+1,631
| New | +$20.1K | ﹤0.01% | 7964 |
|
|
2022
Q3 | – | Sell |
-844
| Closed | -$11K | – | 10282 |
|
|
2022
Q2 | $11K | Sell |
844
-899
| -52% | -$9.32K | ﹤0.01% | 7778 |
|
|
2022
Q1 | $19K | Sell |
1,743
-866
| -33% | -$10K | ﹤0.01% | 7497 |
|
|
2021
Q4 | $40K | Buy |
2,609
+609
| +30% | +$7.97K | ﹤0.01% | 7108 |
|
|
2021
Q3 | $28K | Buy |
2,000
+1,777
| +797% | +$29.7K | ﹤0.01% | 6808 |
|
|
2021
Q2 | $4K | Buy |
+223
| New | +$4.61K | ﹤0.01% | 8648 |
|
UBS Group's AKYA Position: Q3 2025 in Review
UBS Group sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 173,132 shares — an estimated $225K sold.
UBS Group first reported a position in AKYA in Q2 2021 and held it in 16 quarters. The position peaked at $392K in Q1 2025. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- UBS Group reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- UBS Group sold 173,132 Akoya BioSciences shares in Q3 2025, an estimated $225K.
- UBS Group first reported a position in Akoya BioSciences in Q2 2021 and held it in 16 quarters.
- UBS Group's Akoya BioSciences position peaked at $392K in Q1 2025.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.